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Abstract
AIM
To investigate the impact of endoscopic ultrasound-
guided fine-needle aspiration (EUS-FNA) and positron 
Retrospective Study
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emission tomography-computed tomography (PET-
CT) in the nodal staging of upper gastrointestinal (GI) 
cancer in a tertiary referral centre.
METHODS
We performed a retrospective review of prospectively 
recorded data held on all patients with a diagnosis 
of upper GI cancer made between January 2009 and 
December 2015. Only those patients who had both a 
PET-CT and EUS with FNA sampling of a mediastinal 
node distant from the primary tumour were included. 
Using a positive EUS-FNA result as the gold standard 
for lymph node involvement, the sensitivity, specificity, 
positive and negative predictive values (PPV and NPV) 
and accuracy of PET-CT in the staging of mediastinal 
lymph nodes were calculated. The impact on thera-
peutic strategy of adding EUS-FNA to PET-CT was 
assessed.
RESULTS
One hundred and twenty one patients were included. 
Sixty nine patients had a diagnosis of oesophageal 
adenocarcinoma (Thirty one of whom were junctional), 
forty eight had oesophageal squamous cell carcinoma 
and four had gastric adenocarcinoma. The FNA results 
were inadequate in eleven cases and the PET-CT 
findings were indeterminate in two cases, therefore 
thirteen patients (10.7%) were excluded from further 
analysis. There was concordance between PET-CT and 
EUS-FNA findings in seventy one of the remaining one 
hundred and eight patients (65.7%). The sensitivity, 
specificity, PPV and NPV values of PET-CT were 92.5%, 
50%, 52.1% and 91.9% respectively. There was 
discordance between PET-CT and EUS-FNA findings 
in thirty seven out of one hundred and eight patients 
(34.3%). MDT discussion led to a radical treatment 
pathway in twenty seven of these cases, after the final 
tumour stage was altered as a direct consequence 
of the EUS-FNA findings. Of these patients, fourteen 
(51.9%) experienced clinical remission of a median of 
nine months (range three to forty two months). 
CONCLUSION
EUS-FNA leads to altered staging of upper GI cancer, 
resulting in more patients receiving radical treatment 
that would have been the case using PET-CT staging 
alone.
Key words: Endoscopic ultrasound; Oesophago-gastric 
cancer staging; Oesophageal cancer; Positron emission 
tomography-computed tomography; Mediastinal nodes
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: We have found that positron emission 
tomography-computed tomography (PET-CT) in the 
setting of upper gastrointestinal cancer has a high 
sensitivity and negative predictive value, but has poor 
specificity and positive predictive value for the detection 
of malignant mediastinal lymph nodes. This could lead 
to many patients being over-staged by PET-CT alone. 
The use of endoscopic ultrasound-guided fine-needle 
aspiration of mediastinal nodes results in more patients 
being offered radical therapy.
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with upper gastrointestinal cancer: Results from a regional centre. 
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INTRODUCTION
The optimal management of oesophageal or oesophago-
gastric junctional cancer relies on accurate staging to 
ensure that patients are directed towards the most 
appropriate treatment pathway for their stage of 
disease. Surgical resection for patients with localised 
disease offers the best outcomes with five year survival 
rates of 17%-47%[1-3]. It is particularly important to 
ensure that the nodal staging is as accurate as possible 
in these patients so that patients with incurable disease 
avoid radical surgical or oncological therapy but are 
offered a palliative approach. It is equally important 
that potentially curable patients are not incorrectly 
thought to have incurable disease. 
Several imaging modalities are available and when 
used in combination, provide the most accurate stag­
ing in upper gastrointestinal (GI) cancer. The 2011 
United Kingdom joint medical, surgical and oncology 
guideline advised that positron emission tomography­
computed tomography (PET-CT) imaging should be used 
in combination with standard computed tomography 
(CT) and upper GI endoscopic ultrasound (EUS) in the 
assessment and staging of oesophageal and oesophago-
gastric junctional cancer[4]. However in the era of 
relatively widespread use of PET­CT in this setting, the 
exact role of EUS remains unclear[5].
EUS has proven accuracy in both the assessment of 
tumour depth (T staging) and the extent of local nodal 
involvement (N stage) for patients with oesophageal 
and oesophago-gastric junctional cancer[6-8]. Standard 
EUS nodal imaging criteria suggestive of malignant 
lymphadenopathy include node size, border, shape and 
echogenicity. However, in practice, malignant lymph 
nodes rarely exhibit all of these characteristics and even 
with all four characteristics suggestive of malignancy, 
accuracy is sub-optimal[9-11]. To address this issue, other 
imaging techniques including tissue elastography and 
strain ratio have been used to help differentiate between 
benign and malignant mediastinal lymph nodes in upper 
GI cancer[12-15]. However tissue acquisition by EUS­FNA 
remains the optimal way to assess a (non-peritumoural) 
node for malignant involvement. 
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PET-CT imaging has been shown to be more 
accurate than PET alone in loco-regional nodal staging 
of oesophageal cancer[16]. PET-CT is also superior 
to both PET and CT alone in the detection of distant 
metastases[17,18]. It also has the potential to alter the 
staging and management of 12%-18% of patients[19,20]. 
However, it is well recognised that non­malignant 
processes such as inflammation can result in false 
positive findings which will affect the specificity of PET­
CT in this setting. The false positive rate of PET­CT has 
been quoted as between 1.5% and 7.5% in upper GI 
cancer[21-24]. It has also been suggested that this may 
be an underestimate as positive findings are not always 
evaluated further[25]. However some studies have 
reported excellent specificity figures for PET­CT in this 
setting[26-32].
The aim of this study was to analyse the results and 
concordance of PET­CT and EUS­FNA in the staging of 
mediastinal lymph nodes in one tertiary referral centre, 
and to assess the impact of EUS­FNA on deciding the 
final therapeutic pathway.
MATERIALS AND METHODS
Patients
This was a retrospective single centre study. Glasgow 
Royal Infirmary is a regional tertiary referral centre for 
EUS staging of upper GI cancer. Using a prospectively 
collected database, we reviewed the electronically 
held case records of all patients with a diagnosis of 
oesophago-gastric cancer who underwent PET-CT 
and EUS­FNA of at least one mediastinal lymph node 
between the 1st January 2009 and 31st December 
2015. For each identified patient, we reviewed the 
PET­CT radiology report, the EUS­FNA procedure 
report and cytology report in addition to the final 
agreed therapeutic pathway after the conclusive multi­
disciplinary team meeting.
Cases were described as PET­CT positive if me-
diastinal lymph node(s) demonstrated mild, moderate 
or high FDG uptake on imaging as described in the 
radiology report. PET­CT negative cases were those 
cases that demonstrated no uptake in any mediastinal 
lymph nodes. PET-CT indeterminate cases were those 
who demonstrated minimal FDG uptake and were 
excluded from further analysis.
Following PET­CT imaging, all of our patients 
proceeded to have EUS­FNA within (a maximum of) 4 wk, 
but within 10­14 d for the vast majority. After MDT 
discussion, mediastinal nodes of concern distant from 
the primary tumour were targeted for FNA sampling 
(Figures 1 and 2). 
 EUS­FNA positive cases were defined as those 
whose cytology reports confirmed the presence of 
malignant cells in the sampled lymph node consistent 
with origin from their primary upper GI cancer. EUS-
FNA negative cases were defined as those reported by 
the cytologist to show no evidence of malignant cells, 
together with benign lymphocytes consistent with 
lymph node sampling indicating an adequate specimen. 
Samples that did not meet either of these criteria 
were deemed to be insufficient for diagnosis and were 
excluded from further analysis. 
Using a positive EUS­FNA result as the gold standard 
for lymph node involvement, we calculated the 
sensitivity, specificity, positive and negative predictive 
values (PPV and NPV) and accuracy of PET­CT in the 
staging of mediastinal lymph nodes. We also reviewed 
the final tumour stage and patient outcomes to 
determine the influence that EUS­FNA had in the cases 
where there was discordance between the PET-CT and 
EUS­FNA findings.
Instruments and technique
Staging EUS was undertaken by one of three 
experienced endosonographers (SP, NJ, AJS) using a 
Pentax linear ± radial echoendoscope, attached to a 
Hitachi EUB-8500 ultrasound processor. Standard EUS 
grey-scale images of suspicious lymph nodes were 
obtained and conventional characteristics of nodal size, 
shape, distinction of border and density were recorded.
Le
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Figure 1  Positron emission tomography-computed tomography image. 
Positron emission tomography (PET)-computed tomography image of PET 
positive lower oesophageal tumour with uptake in the primary tumour and also 
in high paratracheal and coeliac nodes.
Figure 2  Endoscopic ultrasound-guided fine-needle aspiration image. 
Endoscopic ultrasound-guided fine-needle aspiration of a high mediastinal node 
in upper Gastrointestinal cancer.
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EUS­FNA was performed using a Cook™ 22 gauge 
needle (Figure 2). A minimum of three samples were 
obtained by standard technique, stored in cytolite then 
sent to the laboratory for later cytological analysis by 
specialist pathologists.
Statistical analysis
A cytological report describing evidence or absence of 
malignancy in a sample consistent with lymph node 
sampling was used as the gold standard for analysis. We 
were then able to calculate the concordance of results 
between EUS­FNA and PET­CT. We also calculated the 
sensitivity, specificity, PPV and NPV of PET­CT in the 
identification of malignant mediastinal lymph nodes in 
patients with upper GI cancer.
RESULTS
One hundred and twenty one patients were identified 
in the study period (Table 1). Ninety one (75.2%) 
were male and thirty (24.8%) were female. The FNA 
sample was described as inadequate for analysis by 
the cytologist in eleven cases (8.9%) and the PET­
CT findings were indeterminate in two cases (1.7%). 
These thirteen cases were excluded from further 
analysis. For the remaining one hundred and eight 
patients, sixty two had a histological diagnosis of 
adenocarcinoma (Thirty had oesophageal, twenty eight 
had junctional and four had gastric adenocarcinoma) 
and forty six had oesophageal squamous cell 
carcinoma. Of all these patients, thirty seven were 
positive on both PET­CT and EUS­FNA and thirty four 
were negative on both PET­CT and EUS­FNA, giving 
an overall concordance of 65.7%. The sensitivity, 
specificity, PPV and NPV results of PET­CT were 92.5%, 
50%, 52.1% and 91.9% respectively.
Thirty four (31.5%) patients had positive PET­
CT findings but negative EUS­FNA cytology and 
three (2.8%) patients had negative PET­CT findings 
and positive EUS­FNA cytology (Table 2). There 
were therefore thirty seven patients with discordant 
findings. The final treatment decision was unknown in 
five patients due to the majority of their management 
being undertaken at another health board, having been 
referred to our unit for EUS. For the remaining thirty 
two patients with discordant results, MDT discussion led 
to a radical treatment pathway in twenty seven, after 
the final tumour stage was altered as a consequence 
of the EUS­FNA findings. In all but one case this was 
due to downgrading of tumour stage as a result of 
a negative EUS­FNA in the setting of a positive PET­
CT, however in one case the final tumour stage was 
upgraded due to a positive EUS­FNA but negative PET­
CT result. Five patients were directed to a palliative 
management strategy (Table 3).
When all one hundred and eight cases were taken 
into consideration, EUS­FNA led directly to an alteration 
in clinical stage and subsequent clinical management in 
twenty seven (25%) patients.
In the group of twenty seven patients with discordant 
results who received radical treatment, six (22.2%) had 
progression of their disease whilst receiving treatment. 
Eleven developed progressive disease after completion 
of treatment at a median of nine months (range three 
to forty two months). Four patients remained in clinical 
remission post completion of radical treatment, although 
one of these patients died from urinary sepsis two years 
after completion of therapy. The median duration of 
clinical remission for the fifteen patients (55.6%) who 
experienced this was nine months (range three to forty 
two months).
One patient initially accepted radical treatment 
but refused further treatment after one cycle of neo-
adjuvant chemotherapy. One other patient was not fit 
to have surgical resection after completing neo­adjuvant 
chemotherapy due to deterioration of other medical 
comorbidities rather than disease progression. The follow-
up records after radical treatment were not available in 
four patients (Table 4).
We also analysed the data on the basis of histological 
subtype. For the forty six cases with oesophageal 
squamous cell carcinoma, nineteen were positive on 
both PET­CT and EUS­FNA and fourteen were negative 
on both investigations, resulting in a concordance of 
71.7%. In the sixty two cases with adenocarcinoma 
(which includes oesophageal, junctional and gastric 
adenocarcinoma), eighteen were positive on both PET­
CT and EUS­FNA and twenty were negative on both 
n  = 121
Gender, n (%)
   Male 91 (75.2)
   Female 30 (24.8)
Primary diagnosis, n (%)
   Oesophageal adenocarcinoma 38 (31.4)
   Oesophago-gastric junctional adenocarcinoma 31 (25.6)
   Oesophageal squamous cell carcinoma 48 (39.7)
   Gastric adenocarcinoma 4 (3.3)
Excluded patients 13
   EUS-FNA inadequate 11
   PET-CT indeterminate   2
EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration; PET-CT: 
Positron emission tomography-computed tomography.
Table 1  Patient characteristics
PET-CT positive PET-CT negative
EUS-FNA positive 37 (34.3%) 3 (2.8%)
EUS-FNA negative 34 (31.5%) 34 (31.5%)
EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration; PET-CT: 
Positron emission tomography-computed tomography.
Table 2  Breakdown of results of positron emission tomo-
graphy-computed tomography and endoscopic ultrasound-
guided fine-needle aspiration
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investigations, resulting in a concordance of 61.3%.
DISCUSSION
Upper GI cancer is a significant public health issue, 
accounting for 4% of cancers diagnosed in the United 
Kingdom. The most recent Cancer Research United 
Kingdom statistics from 2014 report an age standardised 
incidence of oesophageal cancer of 15.2 per 100000. 
The corresponding figure for gastric cancer was 11.4 per 
100000 population, giving an overall incidence of upper 
GI cancer of 26.6 per 100000 population[33,34]. In recent 
years, there has been an increase in the use of PET-CT 
for clinical staging[5]. Its role in this setting however is 
controversial[21-25]. We devised this study to assess the 
impact of EUS­FNA in conjunction with PET­CT in the 
staging of patients with upper GI cancer.
We have found that PET­CT has 92.5% sensitivity for 
the detection of metastatic mediastinal lymphadenopathy 
in the setting of upper GI cancer. However, this is offset 
by poor specificity at 50%, leading to false­positive 
mediastinal nodes and the danger of over­staging upper 
GI cancer with PET­CT. Therefore EUS­FNA appears to 
have a critical role in confirming whether suspicious 
nodes identified on PET­CT have malignant involvement, 
in order to optimise staging of this disease. We feel 
that this is the most significant and clinically relevant 
finding of this study. The addition of EUS­FNA to PET­
CT appears to lead to more accurate staging with the 
result of more patients being offered potentially curative 
treatment. After MDT discussion, EUS­FNA led to altered 
tumour stage and subsequent clinical management in 
25% patients.
Our findings contrast with several previous studies 
which reported lower sensitivity but higher specificity 
rates for the detection of malignant mediastinal 
lymph nodes by PET-CT[26-32]. The interpretation of a 
positive mediastinal lymph node on PET­CT imaging 
in these studies seems to have been the same as 
our interpretation in that any FDG uptake beyond 
background level was considered significant. The 
reasons for our different findings remain unclear and 
require further study. 
We looked in detail at the subgroup of 34 patients 
who had PET­CT positive, EUS­FNA negative nodes. 
Perhaps unexpectedly, we found that the majority 
(n = 22) of these patients demonstrated moderate 
or high (rather than just mild) uptake. The reasons 
for this finding are unclear, but do not suggest over­
interpretation of low PET avidity.
Perhaps unexpectedly, we found three cases that 
had PET­CT negative but EUS­FNA positive nodes. All of 
these cases had adenocarcinoma; two were junctional 
and one case had oesophageal adenocarcinoma. Inter-
estingly, we found that one of these cases displayed 
conventional EUS appearances of malignancy despite 
negative PET­CT appearances.
Upon analysis of our findings specifically in the 
context of histological subtype, we found that the 
concordance rate between PET­CT and EUS­FNA was 
71.7% in those with oesophageal squamous cell car­
cinoma compared to 61.3% in those with adenocar-
cinoma. A recent paper which evaluated the extent of 
FDG uptake by malignant lymph nodes in the context of 
lung cancer found no significant difference on the basis 
of histological subtype (Which included adenocarcinoma 
and squamous cell carcinoma)[35]. We could not find any 
similar study which addresses this issue in the context 
of upper GI cancer. This is an area that requires further 
study.
Our study has several limitations. Firstly, this was a 
study which required us to access notes and electronic 
data retrospectively, albeit from a prospectively 
collected database. For some patients, all of the clinical 
information was not available because they received 
their follow-up care outside our tertiary referral centre, 
where the central staging investigations, including EUS 
and PET-CT, were performed. Secondly, the interpretation 
of mediastinal nodal involvement and designation of 
patients as either PET­CT positive or negative was a 
subjective judgement based on the radiological report 
rather than the maximum standardised uptake valves 
(SUVmax), which was only available in a minority of 
these reports. We agree that such data would be useful 
for future studies. Thirdly, the duration of follow-up was 
variable for each patient, although the minimum follow­
up for all patients was 6 mo. This relatively short period 
of follow­up for some patients means that it is difficult 
to compare longer term survival outcomes with those 
reported in other studies. Finally, we accept that PET­
CT and EUS­FNA are indirect ways of assessing for 
malignant involvement of mediastinal lymph nodes in 
the setting of upper GI cancer and that the most certain 
way to do this is by surgical resection. Unfortunately 
however, only a minority of our cases proceeded to 
surgical resection whereas they all had PET-CT followed 
by targeted mediastinal node sampling by EUS­FNA. 
  n = 37
Radical treatment 27
Palliative care   5
Unknown   5
Table 3  Multidisciplinary team decision in discordant cases
Radical treatment  n = 27
Disease progression after completion of treatment 11
Disease progression whilst receiving treatment   6
Clinical remission after completion of treatment   3
Death from other cause whilst in remission   1
Consent for radical treatment withdrawn   1
Had neo-adjuvant chemo but not fit for surgery   1
Unknown   4
Table 4  Outcomes after radical treatment in discordant group
Harrington C et al . EUS-FNA for accurate staging of upper GI cancer
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The lack of surgical findings is a weakness of our study 
but it is reflective of our experience within our tertiary 
referral centre within the study period.
In conclusion and in the context of widespread 
use of PET­CT, we suggest that EUS­FNA remains an 
important diagnostic tool to optimise mediastinal nodal 
staging in upper GI cancer. Use of this modality ensures 
that patients are not potentially overstaged by PET­
CT, and allows them to be directed to the appropriate 
therapeutic pathway after MDT discussion.
ARTICLE HIGHLIGHTS
Research background
Upper GI cancer accounts for 4% of cancers diagnosed in the United Kingdom 
and as such is a significant public health issue. Surgical resection of the primary 
tumour and any involved lymph nodes results in the best outcomes. For this 
to be possible however, the surgical team must be confident that the disease 
is localised. Accurate pre-operative tumour staging is therefore paramount 
before any decisions regarding treatment are undertaken. In keeping with other 
organ systems, tumour staging of the upper digestive tract follows the TNM 
(Tumour, Node, Metastasis) system. The nodal staging of upper GI cancer has 
been an area of controversy. The 2011 United Kingdom joint medical, surgical 
and oncology guideline advised that positron emission tomography-computed 
tomography (PET-CT) imaging should be used in combination with standard 
computed tomography (CT) and upper GI endoscopic ultrasound (EUS) in the 
assessment and staging of oesophageal and oesophago-gastric junctional 
cancer. However in the era of relatively widespread use of PET-CT in this 
setting, the exact role of EUS remains unclear.
Research motivation
Several studies have assessed the role of PET-CT in the nodal staging of upper 
GI cancer. Most studies agree that PET-CT has high levels of sensitivity in the 
detection of malignant mediastinal lymph nodes. However, it is well documented 
that non-malignant processes such as inflammation can result in false positive 
findings which will adversely affect the specificity of PET-CT in this setting. The 
false positive rate of PET-CT has been quoted as between 1.5% and 7.5% in 
upper GI cancer. It has also been suggested that this may be an underestimate 
as positive findings are not always evaluated further. We performed this study 
to evaluate the performance of PET-CT in this setting within our centre and to 
compare this with the findings from other centres.
Research objectives 
The first objective of this project was to evaluate the sensitivity, specificity, 
positive predictive value and negative predictive value of PET-CT in the 
detection of malignant mediastinal lymph nodes in the setting of upper GI 
cancer within the authors’ tertiary referral centre. The second objective was 
to evaluate the impact on subsequent therapeutic strategy that the addition of 
EUS-FNA had in these patients. 
Research methods
The authors performed a retrospective review of prospectively recorded data 
held on all patients with a diagnosis of upper gastrointestinal (GI) cancer made 
between January 2009 and December 2015. Only those patients who had both 
a PET-CT and EUS with FNA sampling of a mediastinal node distant from the 
primary tumour were included. 
Research results
The authors found that EUS-FNA leads to altered staging of upper GI cancer, 
resulting in more patients receiving radical treatment that would have been the 
case using PET-CT staging alone. The authors found that EUS-FNA resulted 
in altered tumour staging and subsequent management in 25% of cases 
included in this study. The authors were also interested to find that the rate of 
concordance of PET-CT and EUS-FNA findings was dependent on the tumour 
histological subtype. There was a 71.7% rate of concordance in cases with 
squamous cell carcinoma compared with 61.3% concordance in cases with 
adenocarcinoma. The reasons for this are unclear and this is therefore an area 
that requires further study.
Research conclusions
The authors suggest that EUS-FNA remains an important diagnostic tool to 
optimise mediastinal nodal staging in upper GI cancer. Use of this modality 
ensures that patients are not potentially overstaged by PET-CT, and allows 
them to be directed to the appropriate therapeutic pathway after MDT 
discussion. Therefore EUS-FNA appears to have a critical role in confirming 
whether suspicious nodes identified on PET-CT have malignant involvement, in 
order to optimise staging of this disease. The authors feel that this is the most 
significant and clinically relevant finding of this study. 
Research perspectives
The authors’ findings contrast with several previous studies which reported 
lower sensitivity but higher specificity rates for the detection of malignant 
mediastinal lymph nodes by PET-CT. The interpretation of a positive mediastinal 
lymph node on PET-CT imaging in these studies seems to have been the 
same as our interpretation in that any FDG uptake beyond background level 
was considered significant. The reasons for our different findings remain 
unclear and require further study. The authors also found that the rate of 
concordance between PET-CT and EUS-FNA findings was greater in patients 
with squamous cell carcinoma than in those with adenocarcinoma (71.7% and 
61.3% respectively). The authors could not find any study which addresses this 
area in the context of upper GI cancer specifically. This is therefore an area that 
requires further study.
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